Medical Condition News

RSS

JDRF selects Convio's Common Ground CRM for primary constituent relationship management

Convio, Inc. announced today that Juvenile Diabetes Research Foundation (JDRF) has selected Convio as their standard for constituent relationship management (CRM), online marketing and fundraising, and special events for JDRF's national headquarters and all chapters. JDRF will use Convio's integrated, on-demand marketing, fundraising and advocacy suite to power and support their efforts to engage constituents and raise money.

13 Sep 2010

Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.

13 Sep 2010

Amorcyte receives patent for chemotactic hematopoietic stem cell product

Amorcyte, Inc., a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that it has been granted United States Patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair." The patent contains both composition of matter and method claims surrounding therapeutic chemotactic hematopoietic stem cell products used in treating or repairing a vascular injury following an acute myocardial infarction (AMI), and delivery of the cell therapy.

13 Sep 2010

Seattle Genetics' lintuzumab phase IIb clinical trial for AML does not meet primary endpoint

Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.

13 Sep 2010

New guidance on making complex decisions about injured athlete's return to play

When is it appropriate for an injured athlete to return to competition? A new three-step framework provides team physicians and other sport medicine clinicians with guidance on making complex decisions about return to play, reported in the September Clinical Journal of Sport Medicine.

13 Sep 2010

Mental illness costs Canadian economy $51 billion in lost productivity

Mental illness is associated with more lost work days than any other chronic condition, costing the Canadian economy $51 billion annually in lost productivity. In the first study of its kind, researchers from the Centre for Addiction and Mental Health (CAMH) have calculated the actual cost of mental health leave and found that on average it's double the cost of a leave for a physical illness.

13 Sep 2010

Leukemia survivor to meet donor of bone marrow transplant

Ann Marie Del Fiacco, a 38-year-old Berwyn mother of two, owes her life to a stranger who volunteered to be a donor for her life-saving bone marrow transplant.

13 Sep 2010

Non-invasive brain stimulation helps paralysed stroke patients regain motor function

Stroke patients who were left partially paralysed found that their condition improved after they received a simple and non-invasive method of brain stimulation, according to research in the September issue of the European Journal of Neurology.

13 Sep 2010

Researchers investigate human reovirus with chemotherapy for ovarian cancer

Researchers are now investigating whether the human reovirus, when prescribed along with chemotherapy, will provide a desperately needed "one-two punch" against ovarian cancer.

13 Sep 2010

Basketball-related traumatic brain injuries increase 70% over 11-year study period

A new study conducted by researchers at the Center for Injury Research and Policy at Nationwide Children's Hospital examined basketball-related injuries treated in emergency departments among children and adolescents between the ages of 5 and 19 from 1997 to 2007. According to the study, more than 4 million basketball-related injuries were treated in emergency departments during the 11-year study. While the number of injuries decreased 22 percent over the course of the study, the average number of injuries per year (375,350) remained high.

13 Sep 2010

CAP forges collaboration with CAP-ACP and RCPA for development of cancer protocols

The College of American Pathologists (CAP) recently signed Memoranda of Understanding (MOUs) with the Canadian Association of Pathologists (CAP-ACP) and the Royal College of Pathologists Australasia (RCPA), forging a collaboration in the development of cancer datasets, also called protocols. The CAP Cancer Protocols are designed as a guideline for definitive cancer reporting.

13 Sep 2010

Cell quality control mechanism research paves way for new understanding of neurodegenerative diseases

Scientists from The Scripps Research Institute have solved a long-standing mystery of how cells conduct "quality control" to eliminate the toxic effects of a certain kind of error in protein production. The findings may lead to a better understanding of a host of neurodegenerative diseases.

13 Sep 2010

Octapharma sponsors symposium on inhibitors in Haemophilia A

In a showing of its continued commitment to eradicating today's major complication in the treatment of haemophilia with FVIII concentrates − i.e. anti-FVIII neutralising antibodies − Octapharma AG recently sponsored a symposium, "Inhibitors in Haemophilia A: Prevention, Current Management and Personalised Therapy Perspectives", on July 13, 2010 at the World Federation of Haemophilia's (WFH's) yearly congress.

13 Sep 2010

Fusion surgery for spondylolisthesis in lumbar spine has long-term benefits: Study

A group of children who underwent fusion surgery for spondylolisthesis in the lumbar spine 30 years ago showed a clear reduction in back pain when followed up seven years later. A new study of these patients as adults has found that the benefits have lasted, reveals research from the Sahlgrenska Academy and Sahlgrenska University Hospital presented this week at the International Society of Orthopaedic Surgery and Traumatology (SICOT) annual international conference in Gothenburg.

13 Sep 2010

Ranier's Cadisc-L spinal disc replacement granted CE Mark Approval

Ranier Technology, the medical device development company focusing on the commercialisation of spinal implants, has announced that it has received CE Mark approval for its Cadisc™-L; an elasto-mimetic spinal disc replacement device for the lumbar spine. The CE Mark approval was received following a review of the company's multi-centre European clinical study and its extensive portfolio of biocompatibility and biomechanical testing.

13 Sep 2010

Santarus expands development pipeline, adds two novel biologic drug candidates

Santarus, Inc., a specialty biopharmaceutical company, has expanded its development pipeline with the addition of two novel biologic drug candidates focused on specialty markets.

13 Sep 2010

Genetic misfolding of neuroligins protein may lead to autism spectrum disorders: Research

An international team of scientists, led by researchers at the University of California, San Diego, has identified misfolding and other molecular anomalies in a key brain protein associated with autism spectrum disorders.

13 Sep 2010

Scientists discover gene associated with myopia

Myopia (nearsightedness) is the most common eye disorder in the world and becoming more common, yet little is known about its genetic underpinnings.Scientists at Duke University Medical Center, in conjunction with several other groups, have uncovered a gene associated with myopia in Caucasian people from several different regions, including Dutch, British and Australian subjects.

13 Sep 2010

Diamyd Medical reports potential results on NP2 Phase I clinical trial for chronic pain

Diamyd Medical AB, to date no drug related Serious Adverse Events have been reported by any patient included in Diamyd's Phase I clinical trial investigating NP2 as a potential therapy for chronic pain. Based upon the Phase I findings to date, the company is planning a multi-center, randomized, double-blind, placebo controlled Phase II clinical trial with NP2 in the United States.

13 Sep 2010

Inovio Pharmaceuticals achieves promising results in VGX-3100 Phase I study

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in its Phase I dose escalation study of VGX-3100, its DNA vaccine to treat pre-cancerous cervical dysplasias and cervical cancers caused by human papillomavirus (HPV) types 16 and 18.

13 Sep 2010

Medical Condition News

JDRF selects Convio's Common Ground CRM for primary constituent relationship management

Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML

Amorcyte receives patent for chemotactic hematopoietic stem cell product

Seattle Genetics' lintuzumab phase IIb clinical trial for AML does not meet primary endpoint

New guidance on making complex decisions about injured athlete's return to play

Mental illness costs Canadian economy $51 billion in lost productivity

Leukemia survivor to meet donor of bone marrow transplant

Non-invasive brain stimulation helps paralysed stroke patients regain motor function

Researchers investigate human reovirus with chemotherapy for ovarian cancer

Basketball-related traumatic brain injuries increase 70% over 11-year study period

CAP forges collaboration with CAP-ACP and RCPA for development of cancer protocols

Cell quality control mechanism research paves way for new understanding of neurodegenerative diseases

Octapharma sponsors symposium on inhibitors in Haemophilia A

Fusion surgery for spondylolisthesis in lumbar spine has long-term benefits: Study

Ranier's Cadisc-L spinal disc replacement granted CE Mark Approval

Santarus expands development pipeline, adds two novel biologic drug candidates

Genetic misfolding of neuroligins protein may lead to autism spectrum disorders: Research

Scientists discover gene associated with myopia

Diamyd Medical reports potential results on NP2 Phase I clinical trial for chronic pain

Inovio Pharmaceuticals achieves promising results in VGX-3100 Phase I study

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Latest News